Current Research Studies
ACNS1833, A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727, IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)
ACNS1833
- Condition(s): Behavioral, Pilocytic Astrocytoma, Other, Low-Grade Glioma, Brain Tumor, Newly diagnosed
- Phase: III
- Clinicaltrials.gov ID: NCT04166409
What is the goal of the study?
To demonstrate that the efficacy of treatment with selumetinib as measured by event-free survival (EFS) is non-inferior compared to treatment with carboplatin/vincristine (CV) in previously-untreated low-grade glioma (LGG) not associated with BRAFV600E mutations or systemic neurofibromatosis type 1 (NF1).
Who can participate in the study?
Please contact the study team listed below to learn more.
Study Team:
- PI (Study Doctor): Aimee Sato
- Study Team Member: HemOnc CRAs, [email protected]